

City Research Online

City, University of London Institutional Repository

Citation: Gardulf, A., Abolhassani, H., Gustafson, R., Eriksson, L. E. & Hammarström, L. (2018). Predictive markers for humoral influenza vaccine response in patients with common variable immunodeficiency (CVID). Journal of Allergy and Clinical Immunology, 142(6), 1922-1931.e2. doi: 10.1016/j.jaci.2018.02.052

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: https://openaccess.city.ac.uk/id/eprint/19584/

Link to published version: https://doi.org/10.1016/j.jaci.2018.02.052

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. City Research Online: <u>http://openaccess.city.ac.uk/</u> <u>publications@city.ac.uk</u>

1 Predictive markers for humoral influenza vaccine response in

2

patients with common variable immunodeficiency (CVID)

- 3 Ann Gardulf, RN, PhD^{1,2}, Hassan Abolhassani, MD, PhD^{1,2,7}, Rolf Gustafson, MD, PhD³,
- 4 Lars E. Eriksson, RN, MSc, PhD^{4,5,6}, Lennart Hammarström, MD, PhD^{1,2}
- 5 ¹Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory
- 6 Medicine, Karolinska Institutet, Campus Flemingsberg, Huddinge, SE-141 86 Stockholm,
- 7 Sweden
- 8 ²Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Karolinska
- 9 University Hospital, Campus Flemingsberg, Huddinge, SE-141 86 Stockholm, Sweden.
- ³The Immunodeficiency Unit, Department of Infectious Diseases, Karolinska University
 Hospital, Huddinge, SE-141 86 Stockholm, Sweden.
- ⁴ Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, SE-171
 77 Stockholm, Sweden.
- ⁵Division of Nursing, School of Health Sciences, City, University of London, London EC1V
 0HB, UK.
- ⁶Department of Infectious Diseases, Karolinska University Hospital, Huddinge, SE-141 86
 Stockholm, Sweden.
- ⁷Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's
 Medical Center, Tehran University of Medical Sciences, Tehran, Iran
- 20

21 **Corresponding author:** Ann Gardulf

Address: Department of Laboratory Medicine, Division of Clinical Immunology and
Transfusion Medicine, Alfred Nobels allé 8, Karolinska Institutet, Huddinge, SE-141 86
Stockholm, Sweden

25	E-mail:	ann.gardulf@ki.se.

26

27	Running title:	Humoral res	ponse to .	A(H1N1)	pandemic	influenza	vaccine i	n CVID
----	-----------------------	-------------	------------	---------	----------	-----------	-----------	--------

28

29 Statement of financial sources: The study was funded by the Jeffrey Modell Foundation,

30 New York; the Swedish Research Council, Stockholm, Sweden; and research funds from

31 Karolinska Institutet, Stockholm, Sweden.

- 33 **Conflict of interests:** The authors declare that there was no financial or personal relationship
- 34 with third parties whose interests could be positively or negatively influence the content.

35 Abstract

Background: A subgroup of patients with common variable immunodeficiencies (CVID)
responds to vaccination. The aim of the study was to try to identify predictive markers for
those who developed a humoral immune response after influenza vaccination.

Methods: 48 patients with CVID (29 females, 19 males, mean age 59.4 years) were vaccinated with the A(H1N1) influenza vaccine Pandemrix[®] and boosted after one month. Blood samples were collected prior to each vaccination and two months later. Patients with a 42 4-fold titer increase of the hemagglutinin inhibition test (\geq 1:40) were considered responders and compared to non-responders for clinical, immunological and genetic markers.

Results: Eight (16.7%) patients responded to the vaccination. A significantly higher 44 proportion of the responders, who showed a Euroclass SmB⁻Tr^{norm}21^{norm} profile (p=0.03) with 45 a post-germinal center B cell pattern (p=0.04) in blood, suffered from enteropathies (p=0.04) 46 as compared to non-responders. Bronchiectasis on the other hand, was exclusively found 47 among non-responders (n=7), as was autoimmune cytopenia (n=5). Non-responders with a 48 Euroclass SmB⁻21^{low}Tr^{norm} profile (p=0.02), had a significantly higher prevalence of 49 progressive antibody deficiency (p=0.048) and, at diagnosis, a higher mean serum IgM level 50 51 (p=0.03), a lower mean serum IgG1 level (p=0.007), an expansion of absolute counts of cytotoxic CD8⁺ T-cells (p=0.033) and an increased proportion of memory CD8⁺ T-cells 52 (p=0.044) in blood. CVID associated HLA markers were not detected in non-responders 53 54 (p=0.03).

Conclusion: About one-fifth of the CVID patients achieved protective antibody levels after
A(H1N1) vaccination and selected clinical and immunological markers were identified that
may predict a positive outcome of influenza vaccination.

58 Key messages:

A subgroup of patients with CVID develops a humoral immunological response from
 influenza vaccination.

Selected clinical and immunological markers may help to identify a possible positive
 influenza vaccination outcome and are enteropathy, Euroclass SmB⁻Tr^{norm}21^{norm} and
 post-germinal center B-cell pattern.

HLA CVID genetic predisposing markers, pronounced IL-12 production and Th1
 polarity were observed only in non-responders.

Despite the fact that not all patients with CVID will develop protective antibody levels
 after influenza vaccination it is concluded that they should be offered this prophylactic
 measure due to the potential severity of influenza and risk for bacterial complications.

69

70 **Capsule Summary:** One-fifth of the patients with CVID vaccinated against pandemic 71 influenza A(H1N1) converted to $a \ge 1:40$ titer of specific antibodies against the antigen and 72 selected clinical and immunological predictive markers were identified in this subgroup.

73

Keywords: Common variable immunodeficiency, CVID, specific antibody deficiency,
vaccination, influenza, pandemic influenza, immune response, A(H1N1), Pandemrix

- 76 Abbreviations:
- 77 **CVID:** Common variable immunodeficiency
- 78 **DNA**: Deoxyribonucleic acid
- 79 **ELISA**: Enzyme-linked immunosorbent assay

80 **HA**: Hemagglutinin

81 **HI**: Haemagglutination inhibition

82 HLA: Human leukocyte antigen

83	Igs: Immunoglobulins
84	IFN- <i>γ</i> : Interferon gamma
85	IL: Interleukin
86	PBS : Phosphate-buffered saline
87	PCR : Polymerase chain reaction
88	PID: Primary immunodeficiency disorder
89	PHA: Phytohemagglutinin
90	RDE: Receptor-destroying enzymes
91	WHO: World Health Organization
92	

93 Introduction

Common variable immunodeficiency (CVID) is a heterogeneous primary immunodeficiency disorder (PID) characterized by low serum concentrations of immunoglobulins (Igs) and impaired specific antibody production.¹⁻³ Specific antibody deficiency is a diagnostic criterion in most of the standard clinical guidelines and constitutes the absence of natural Igs (e.g. isohemagglutinins) or poor response to novel protein or polysaccharide antigens (e.g. in vaccines).^{2, 4, 5}

Approximately 10-20% of clinically diagnosed patients with CVID have a residual 100 response to vaccination against protein antigens and, to a lesser extent, against polysaccharide 101 antigens.⁶⁻¹² The heterogeneity in specific antibody defects in CVID patients may be due to 102 the association of this complex disease with several different genetic defects.^{13, 14} Although it 103 is uncertain whether vaccination with killed/inactivated vaccines will protect an individual 104 with CVID, the use of these vaccines is nevertheless recommended for diagnostic purposes.¹⁰, 105 Moreover, the use of killed/inactivated vaccines to patients with PID is indeed 15 106 recommended to follow the same schemes as in general populations.¹⁶ 107

108 Current evidence suggests that a subgroup of patients with CVID is not only capable of 109 re-stimulation *in vitro* for production of class-switched Igs but may show residual antibody 110 production *in vivo*.¹⁷⁻¹⁹ Characterization of this subgroup of patients regarding their clinical, 111 immunological and genetic profile could potentially help developing targeted therapy for 112 these patients^{18, 20} and provide evidence-based advises regarding administering influenza 113 vaccine to patients with CVID.

To our knowledge, the immunological response to the same antigen as used in the current study - A(H1N1) pandemic influenza vaccine (antigen X179a 2009, Pandemrix[®]) - has so far only been investigated in three patients with CVID and one patient with X-linked agammaglobulinemia in a 3-months long follow-up study.¹⁹ Two of the patients with CVID responded to the vaccination by a >4-fold rise in haemagglutination inhibition (HI) antibodies

and all three showed a Th1-cell response. It was concluded that some patients with CVID
might produce an influenza-specific humoral immune response, but that this should be
confirmed in larger studies.

The aim of the study was to try to identify clinical, immunological and genetic predictive markers for those patients with CVID who developed a humoral immune response after influenza vaccination. This was performed by investigating to what extent a group of patients with CVID responded to vaccination by producing protective antibodies against the glycopeptide pandemic influenza A(H1N1) antigen.

127 Material and methods

The present study had a prospective design, monitoring patients with CVID before and up to
one year after vaccination with the pandemic influenza A(H1N1) vaccine (Pandemrix[®],
GlaxoSmithKline, Belgium).

131

132 *Patients*

Patients with CVID cared for and receiving Ig replacement therapy at the 133 Immunodeficiency Unit at the Karolinska University Hospital in Stockholm, Sweden, and 134 who had not already been vaccinated against the A(H1N1) pandemic virus were invited to 135 participate in the study carried out during 2010-2011. None of the patients used any steroids 136 or any other immuno-suppressive therapy during the study period and 3 months prior to study 137 start. All patients had been diagnosed as having CVID based on the diagnostic criteria 138 139 established by the European Society for Immunodeficiencies (http://esid.org/WorkingParties/Registry/Diagnosis-criteria) and the American Academy of 140 Allergy, Asthma and Immunology practice parameter for the diagnosis and management of 141 PID.^{4, 21} Before study start, all patients were re-evaluated for fulfilling the diagnostic criteria 142 of CVID and secondary causes of dysgammaglobulinemia were ruled out.²² None of the 143 invited patients presented with protein losing enteropathy, nor with pre-study protective 144 A(H1N1) pandemic virus antibody levels (>1:40 titer). 145

Fifty-seven patients gave their informed consent and volunteered to participate in the study by receiving the first dose of the vaccine. Nine patients (five women and four men, mean age 48.8±20.3) dropped out of the study; seven at the first follow-up visit and two patients at the second follow-up visit. Totally 48 patients (60.4% females) participated in all appointments and were included in the final vaccine response analyses. Forty-seven of the patients received regular weekly subcutaneous (minimum 100 mg/kg/week) and one patient received monthly intravenous (400 mg/kg/month) Ig replacement therapy before and during

the entire study period. Different brands were used but each patient received the same brandand batch of Ig at least three months before and at least until the last blood sampling.

An evaluation document was used to summarize the demographic information of each patient including age at diagnosis, family history and history of previous vaccinations shown as specific antibody responses, and clinical, immunological and genetic data.

158

159 *Study overview*

The A(H1N1) pandemic influenza vaccine Pandemrix[®], a monovalent X179a 2009 160 vaccine, was injected intramuscularly at study start and boosted once after one month. In each 161 vaccination dose, 3.75 µg of hemagglutinin (HA) of the X179a antigen was administered. At 162 study start, concentrations of total IgG, IgG subclasses, IgA and IgM were determined in fresh 163 serum samples taken immediately prior to the next Ig substitution. Specific antibody titers for 164 165 antibodies against the pandemic influenza A(H1N1) antigen were measured in samples collected prior to the first and the second vaccination and also two months after the second 166 167 dose. Follow-up visits due to the vaccine study were scheduled for the patients at regular intervals until one year after study start for the recording of any influenza-like symptoms 168 and/or incidental side effects of the vaccination. 169

170

171 Investigation and definition of vaccination response

One volume of serum was treated with four volumes of neuraminidase receptor destroying enzyme (RDE, Seiken, Japan) in phosphate-buffered saline (PBS) at 37° C overnight before inactivation at 56°C for 30 minutes to prevent non-specific inhibition. Serial two-fold dilutions of RDE treated sera were then incubated with eight haemagglutinating units of the X179a pandemic influenza A(H1N1) antigens for one hour, followed by the addition of 0.7% ([volume of solute/volume of solution] ×100%) turkey erythrocytes. After 30 minutes of incubation, the HA inhibition titers were read as the reciprocal of the highest

dilution at which 50% HA was inhibited. Each serum sample was run in duplicate in two 179 independent experiments and the titers are presented as a mean of these two experiments for 180 each patient. 181

A positive response to the pandemic influenza A(H1N1) antigen was defined as a 4-fold 182 titer increase of the HA inhibition test ($\geq 1:40$).²³ Patients with such increase are hereinafter 183 referred to as responders. 184

185

Clinical and immunological phenotyping and immunological assays 186

The clinical phenotyping of the 48 patients was based on the suggested division into 187 distinct clinical phenotypes by Chapel et al.²⁴ and included patients with infections but no 188 other disease-related complications or patients with infections and autoimmunity, infections 189 and enteropathy and/or infections and polyclonal lymphocytic infiltration. Patients with ≥ 3 190 191 clinical findings were classified as overlapping phenotypes. Clinical data were collected from the medical and nursing records and covered the time from diagnosis to the study start. 192

Thirty-eight of the patients had previously been classified based on two main 193 classifications for B-cell subsets including the Paris, Freiburg, EUROclass²⁵ and the B-cell 194 pattern classification.²⁶ In 27 of the patients, ionizing radiation sensitivity assays had 195 previously been performed on primary fibroblasts irradiated with different doses and serial 196 dilutions.²⁷ This is a method used for classification of patients with CVID and defective DNA 197 repair machinery required for variable (V), diversity (D) and joining (J) genes rearrangement 198 and class-switch recombination.²⁸⁻³¹ 199

Peripheral blood monoclonal cells from all 48 patients were stimulated for 48 hours with 200 phytohemagglutinin (PHA) and cytokine production of interferon gamma (IFN- γ), interleukin 201 2 (IL-2), IL-5, IL-10 and IL-12 were measured by enzyme-linked immunosorbent assay 202 (ELISA) using a method described previously.³² 203

205 Screening of positional candidate genetic markers

HLA-A, -B, -DO and -DR alleles were determined using low-resolution DNA-based 206 typing (polymerase chain reaction [PCR]/sequence specific oligonucleotide probe).³³ The 207 PCR amplification of tumour necrosis factor receptor superfamily member 13 B and C 208 (TNFRSF13B and TNFRSF13C) and their Sanger sequencing were performed using primers 209 and conditions as previously described.³⁴ Of note, selected monogenic forms of PID were 210 excluded in studied patients according to the CVID diagnostic criteria using a targeted gene 211 212 panel sequencing (covering 260 known monogenic diseases) including BTK, BLNK, CD79A, CD79B, IGHM, IGLL1, TCF3, CD19, CD20, CD21, CD81, AICDA, UNG, INO80, MSH6, 213 CARD11, NFKB1, NFKB2, PI3KCD, PIK3R1, PTEN, DOCK2, IKAROS, IRF2BP2, MOGS, 214 TWEAK, IL21, IL21R, LRBA and CTLA4 genes. Moreover, whole exome sequencing in 17 215 patients were also performed, but neither non-responders nor responders had a confirmed 216 217 candidate monogenic disease.

218

219 Ethical considerations

The World Health Organization declared in June 2009 that the outbreak of A(H1N1) influenza fulfilled the criteria of a pandemic situation. As a consequence, the National Board of Health and Welfare in Sweden recommended the general population to be vaccinated and certain risk groups, including individuals with an impaired immune system, to be prioritized. The pandemic influenza A(H1N1) vaccine had not previously been used in a mass vaccination situation, but the potential severity of the disease motivated patients with CVID to be offered the new vaccine.

Based on the Ethical Review of Research Involving Humans³⁵ the vaccination including blood sampling and follow-up schedule were approved by the regional Ethical Committee (approval number 2009/1646-31-3). The patients were given oral and written information

about the study. The principle of volunteering was emphasized and informed written consentto participate including a one-year follow-up was obtained from all patients.

232

233 Statistical analyses

Statistical analyses were performed using SPSS (version 21.0.0, Statistics software, 234 SPSS, Chicago, Illinois) and R statistical systems (version 3.4.1., R Foundation for Statistical 235 Computing, Vienna, Austria). The one-sample Kolmogorov-Smirnov test was applied to 236 237 estimate whether the data distribution was normal and based on the findings of this evaluation independent T-test (in normal distributions) and Mann-Whitney U test (in skewed 238 distributions) were used to compare continuous variables between responders and non-239 responders. Differences in categorical variables between responders and non-responders were 240 examined using χ^2 tests and Fisher's exact tests (the latter when variables had a low 241 frequency). Pearson's correlation coefficient analysis was used to investigate the relationship 242 between specific antibody responses to different antigens. A p-value of 0.05 or less was 243 244 considered statistically significant.

245 **Results**

Three months after the first vaccine dose and two months after the second dose, eight 246 (16.7%) patients had reached a \geq 1:40 titer of specific antibodies against the pandemic 247 influenza A(H1N1) antigen (responders) whereas the remaining 40 patients (83.3%) were 248 considered as non-responders. The production of specific antibodies against the antigen is 249 depicted in **Figure 1**. Four out of eight responders reached protective levels already after the 250 first vaccine dose. Comparing the four early responders with the four late responders, no 251 252 significant differences could be found between their current age (57.0±14.7 vs. 54.2±11.7 years) or age at CVID diagnosis (41.5±10.0 vs. 39±16.8 years). 253

During the study period, none of the patients showed any clinical symptoms of having been infected with the ongoing pandemic influenza A(H1N1) and during the one-year followup period, no influenza-like symptoms and/or negative side-effects other than local reactions on the injection sites were reported.

Table 1 summarizes the demographic and essential immunological data of responders 258 259 and non-responders. Response to the A(H1N1) pandemic vaccine was independent of the 260 gender of the patients. There were also no significant differences in the mean age at diagnosis, mean age at study start, mean years from onset of infections to diagnosis or the mean follow-261 up time after the CVID diagnosis between responders and non-responders, respectively. Nine 262 263 patients had a familiar form of CVID, all belonging to the non-responder group. In the total group, 14 individuals (29.1%) had evolved from an IgA deficiency (n=12) and/or IgG 264 subclass deficiency (n=2) to a CVID diagnosis during the course of their disease. All these 14 265 patients were non-responders constituting 35.0% of this group (p=0.048, compared to absence 266 of this progressive PID form in responders) (Table 1). 267

Regarding the Ig replacement therapy there was no difference in the distribution of different Ig brands used between responders and non-responders (data not shown).

270

271 Clinical phenotyping

Before diagnosis, all 48 patients had experienced recurrent upper respiratory tract infections and 44 had also been diagnosed as recurrently suffer from lower respiratory tract infections (bronchitis and/or pneumonia). Clinical phenotyping of the 48 patients revealed that 14 (29.2%) of them presented with infections without any other disease-related complications, 14 (29.2%) by infections and autoimmunity, four (8.3%) by infections and enteropathy, and three (6.2%) by infections and polyclonal lymphocytic infiltration. Thirteen patients (27.1%) also manifested overlapping phenotypes (**Figure 2, Table S2**).

When dividing the clinical phenotyping between responders and non-responders the proportion of patients with infections without any other disease-related complications was 12.5% among the responders and 32.5% among the non-responders (p=0.12) (**Figure 2, Table S2**). Lower respiratory tract infections were documented in five responders (62.5%) and in 33 non-responders (82.5%, p=0.20). None of the responders showed signs of bronchiectasis, while seven non-responders (17.5%; p=0.10) suffered from this condition.

The phenotype infections and enteropathy was significantly higher in responders (50%
vs. 0%, *p*<0.001). Although infections and autoimmunity was present in about the same
proportion in both groups (25% in responders and 30% in non-responders, n.s.) (Figure 2,
Table S2), autoimmune cytopenia was exclusively observed among the non-responders (n=5).
Malignancies were recorded in 12 patients (30%) in non-responders, mainly due to
thymoma and lymphoma and in two patients (25%) among the responders (one breast cancer
and one colon cancer) (p=0.3882) (Table S2).

No significant difference was observed regarding the proportion of patients with IgE mediated atopic disorders: four responders (50%) and nine non-responders (22.5%, p=0.12) (Table S2).

295

296

297 Immunological phenotyping and classification

At the time of the CVID diagnosis, a significantly higher mean serum level of IgM 298 $(34.8\pm29.6 \text{ vs. } 17.0\pm16.0 \text{ mg/dl}; p=0.03)$ and a significantly lower mean serum level of IgG1 299 $(122.4\pm96.3 \text{ vs. } 219.2\pm198.3 \text{ mg/dl}; p=0.007)$ were noted in non-responders as compared to 300 responders. Lymphocyte subset analyses showed an expansion of absolute counts of cytotoxic 301 T-cells (p=0.033) as well as an increased proportion of memory CD8⁺ T-cells (p=0.044) in the 302 non-responders as compared to the responders. Furthermore, there was a tendency of a higher 303 304 number of NK-cells among the non-responders as compared to the responders (p=0.06). There was no significant difference between responders and non-responders regarding absolute B-305 cell counts, although the non-responders presented a decreased number of plasmablast and an 306 increased CD21^{low} percentage (p=0.007 and p=0.041, respectively) (**Table 2**). 307 Radiosensitivity was only documented in the group of non-responders (4/20 tested non-308 309 responders, 20%, vs. 0/7 tested responders, p=0.09).

Although a positive correlation was observed in responders with increment in the level of protective antibodies after the vaccination with the pandemic influenza A(H1N1) antigen regarding the production of other specific antibodies against protein and polysaccharide antigens (r=0.75, p=0.08), no statistically significant differences were found between responders and non-responders. Details of the humoral immune response to other antigens are presented in **Table S1**.

Immunological classification of the patients revealed that the most frequent immune profile in the responders was Euroclass SmB⁻Tr^{norm}21^{norm} (p=0.03) and post-germinal center B-cell pattern (normal naïve, transitional, marginal and memory B-cell subsets) (p=0.04) as compared to the non-responders, whereas the most frequent immune profile of nonresponders was Euroclass SmB⁻21^{low}Tr^{norm} (p=0.02 compared to the responders) (**Figure 3**).

321	The PHA induced cytokine production in vitro in responders and non-responders are
322	presented in Figure 4. A significant difference was found in mean IL-12 levels; in non-
323	responders 1,081.2 \pm 651.3 pg/ml and for responders 283.3 \pm 256.5 pg/ml (p =0.007).
324	
325	Genetic markers associated with CVID and pandemic influenza A(H1N1) antibody
326	production
327	Four patients with TNFRSF13B (10%) and one patient with TNFRSF13C (2.5%) CVID
328	susceptibility variants were found among the non-responders while only WT TNFRSF13
329	genes were identified among the responders (12.5% vs 0%, $p=0.38$). HLA markers associated
330	with CVID were detected in 16/40 (40%) of the non-responders; HLA-DR3-DQ2 in six
331	patients, HLA-A1-B8 in six patients and HLA-A2-B44 in four patients. HLA markers
332	associated with CVID were not found in any of the responders (40% vs 0%, $p=0.03$).

333 Discussion

The outbreak of the pandemic influenza A(H1N1) and the recommendation to 334 specifically vaccinate individuals with an impaired immune system did not only stress the 335 immediate medical need to offer this new vaccine with a A(H1N1) clade selected by WHO to 336 patients with CVID, but it also opened up a possibility for a scientific evaluation of the 337 vaccination in this group of individuals. The background to the study was the perpetual 338 discussion whether patients with CVID should routinely be offered vaccination against 339 seasonal influenza. Only our study and the study by Pedersen *et al.*¹⁹ have presented data from 340 the use of the specific antigen X179a to individuals with CVID. Our study was designed as an 341 evaluation within the group of patients and therefore no healthy controls were included. 342 However, it has been shown that between 67-98.3% of healthy adults produce protective 343 levels of antibodies against the influenza A(H1N1) vaccine Pandemrix[®] 21days after a single 344 dose of 3.75 μ g of the vaccine. ^{36, 37} 345

Cross-reactive A(H1N1) antibodies are present in healthy populations³⁸ and consequently, antibodies against the pandemic influenza A(H1N1) antigen may be present in Ig preparations.³⁹ All participants in the study were therefore tested for pre-excising A(H1N1) antibodies before entering the study. One 73-year old male had a HA inhibition titer of 1:10 at the study start but this patient did not respond to the vaccination. All patients continued with the same brand and batch of Ig during the study period.

The WHO declaration in 2009 of a pandemic situation in 74 countries and territories rapidly led to a demand for the vaccine that was greater than the supply. On a European level it was considered important to offer the vaccine rapidly to as many individuals as possible. For this reason it was decided by the authorities to start the vaccination campaign with an antigen dose of 3.75 μ g to the entire population but immunodeficient patients were to be offered a second dose after one month. It has later been shown that a single dose of 3.75 μ g of Pandemrix[®] with the antigen X179a brings about immunity to protective level in healthy

adults and elderly.⁴⁰ In the study by Pedersen *et al.* about the immunological response to the 359 antigen X179a in CVID¹⁹, the intention was to give two doses of 3.75 μ g to three patients 360 with CVID but the patients were accidentally given a double dose of Pandemrix[®] at study 361 start. Two of the patients were then given a second dose of 3.75 µg after three weeks whilst 362 the third patient declined being given the second dose. The two patients receiving two doses 363 $(7.5 \,\mu\text{g} + 3.75 \,\mu\text{g})$ responded with a >4-fold humoral response while the patient receiving one 364 dose (7.5 µg) had a HI titer below \geq 1:40. In our study, four of the responders developed 365 protective levels of antibodies against the X179a antigen already after one dose of 3.75 µg, 366 while the four others needed two doses to produce protective levels of antibodies (Figure 1). 367 The four early responders were not older at diagnosis or study start than the four late 368 responders, which could have explained the result as older patients might have been in contact 369 with cross-reactive antigens earlier. Based on the current study and the study by Pedersen et 370 al.¹⁹, it seems reasonable to assume that two doses of 3.75 µg of the antigen X179a would be 371 required to obtain humoral immunity in patients with CVID. Whether these patients should be 372 373 offered one or two doses of inactivated seasonal influenza vaccine has never been addressed 374 in the four groups of patients with CVID where the outcome of this type of vaccine has been investigated^{9, 17, 41, 42} and any answer to this question is therefore not available. However, Eibl 375 & Wolf¹⁶ suggest that the primary immunization of inactivated influenza vaccine should 376 377 follow the same scheme as for healthy individuals, but that more frequent booster immunizations might be necessary depending on the assessment of vaccination response in 378 PID. 379

In the influenza, polysaccharide or protein vaccine studies that have been conducted in patients with CVID^{7, 9, 19, 41-44} they have shown more frequent and earlier decline in antibody responses against polysaccharides compared to proteins, suggesting a preservation of T celldependent specific antibody response in a subgroup of patients.^{7, 19, 43} In a previous study, Zhan *et al.*⁴¹ reported generation of specific IgG-secreting memory B cells post seasonal

influenza vaccines in 50% of the studied CVID patients. In our study, we found that about
one-fifth (16.7%) of the patients responded by producing protective levels of antibodies
against the pandemic influenza A(H1N1) antigen. Consistent with other reports, we also
observed a functional classification of CVID patients, according to the level of the response to
the vaccine.^{43, 45}

There are to date no studies regarding the clinical phenotypes of patients who seroconvert 390 or not after influenza vaccination.⁴⁶ The finding among the responders of a significantly 391 higher proportion of enteropathies, a phenotype that usually presents due to increased 392 apoptotic bodies in the gastrointestinal crypts⁴⁷, may suggest that the immunological 393 phenotype of the responders with normal B cell subsets could be a result of an increased 394 apoptosis of the long-term plasmacells. In line with this notion these patients can produce 395 normal antibodies against specific antigens during a short-term, but these antibody-producing 396 397 plasmacells subsequently disappear. The increased susceptibility to apoptosis in the gastrointestinal crypts could be a trigger of chronic inflammation. Regarding the severe lower 398 399 respiratory tract infections and the bronchiectasis among the non-responders it appears that 400 the non-responders are less likely to mount an immune response against bacteria and consequently an effective elimination in the lower respiratory tract, resulting in persistent 401 tissue damage in the lungs. 402

The capability to respond to certain vaccines *in vivo*, strongly suggest that some patients 403 with CVID can produce class-switched isotypes, as has been shown by cytokine stimulation 404 in vitro.⁴⁸ Although CD27⁺ IgD⁻isotype-switched memory B cells are generally reduced in 405 CVID patients⁴⁹, our findings confirm that responders had a higher level of plasmablasts and 406 lower counts of CD21^{low} B cells (compatible with a Euroclass SmB⁻Tr^{norm}21^{norm} and post-407 408 germinal center B-cell pattern). In contrast, we found that the non-responders at diagnosis presented with lower mean serum level of IgG1 and a higher mean serum level of IgM, 409 highlighting a severe defective class switching recombination in this group of patients. 410

Moreover, radiosensitivity was only found in non-responders but this test was performed only in 27 patients and the difference was not statically significant. These findings emphasize the role of the class-switching capability for developing a vaccine response. In two studies by Goldacker *et al.*⁷ and Chovancova *et al.*¹³, respectively, they presented B cell subset analysis; both reported that group II of the Freiburg classification or the EUROclass group smB+, which represent patients with CVID with nearly normal numbers of class-switched memory B cells, constitutes patient with measurable antibody responses.

Stimulating peripheral blood mononuclear cells with PHA enhanced the production of IL-418 12 at significantly higher mean level in non-responders as compared to responders, suggesting 419 a significant immune regulation in this group toward activation of cellular immunity. Up-420 regulation of the IL-12 as an initial factor in a subgroup of patients with CVID skews the 421 immune response away from Ig production towards a polarized Th1-type chronic 422 inflammation.^{50, 51} Increased expression of the IL-12β1 receptor has also been reported in 423 these patients.⁵² Although the IFN- γ level, another marker of Th1-response, did not differ 424 between the two groups, Ig replacement may alter the serum pattern of this cytokine but not 425 the IL-12 level.⁵³ Failure of an immune deviation from a systemic Th1 response to a Th2 426 immune response may explain the mechanism responsible for the numerically lower 427 proportion of IgE mediated atopic diseases observed in the non-responders as compared to 428 responders.54 429

Humoral response against influenza vaccine has been shown to be the major source of protection against infections and individuals with annual injections have a broader antibody recognition profile after pathogenic confrontation.⁵⁵ However, influenza-specific CD8+ T cells can be generated after vaccination targeted to conserved viral proteins (nucleoprotein and the matrix protein) to provide heterosubtypic immunity. Since long-term annual vaccination in the presence of normal humoral immunity may interfere the induction of heterosubtypic immunity, it can be hypothesized that virus-specific CD8+ T cell responses are

more pronounced in patients with antibody deficiency.⁵⁶ As the current study only focused on
humoral immunity, further evaluation of the cellular immunity in these patients may be of
considerable interest.

The presence of the familiar form of CVID only in non-responders, taken together with 440 the finding of predisposing HLA and non-HLA factors, suggest a strong association of CVID 441 pathogenetic in this group of patients.⁵⁷ Moreover, the progressive primary antibody 442 deficiency was exclusively found in the non-responders, a phenomenon that has previously 443 been linked to genetic susceptibility markers in patients with CVID, in particular HLA A1, 444 B8, DR3 and DQ2.^{58, 59} Investigation of non-genetic etiologies among responders should be 445 prioritized, including epigenome and microbiome assays. The essential role of specific HLA 446 haplotype in response to vaccine has been investigated also in healthy individuals; particularly 447 CVID HLA susceptibility markers such as DQ2-DR3 phenotypes have been linked with non-448 responsiveness to hepatitis B antigen in vaccine in the normal population.^{60, 61} Specific 449 antibody response to vaccines has also been investigated in patients with TNFRSF13B 450 451 mutated alleles and transmembrane activator and CAML interactor (TACI) knockout mice due to the role of TACI in signaling for induction of Ig class switching. Most of the animal studies 452 have showed consistent defective responses to vaccination with T independent antigens.⁶² 453 However, humans with heterozygous TNFRSF13B mutations show a wide range of ability to 454 respond to vaccine from absent to some antibody production $^{63, 64}$ even within the same family 455 with same mutation⁶⁵, suggesting a presence of other genetic modifier rather than TACI. 456

To summarize, we identified protective increment in the level of antibodies against the pandemic influenza A(H1N1) antigen in eight (16.7%) patients of our study population including totally 48 individuals. This is to date the largest study performed investigating influenza vaccine response in patients with CVID. We found that a positive outcome of the influenza vaccination might be expected in patients with certain identified specific B cell patterns. The responders were sporadic cases without genetic susceptibility markers, but with

463 normal class switching recombination and DNA repair machinery. Therefore they could still 464 produce residual specific antibodies against the current antigen, and they presented with low 465 rate of severe lower respiratory tract infections and no infectious complications such as 466 bronchiectasis. Instead, these patients more often presented with enteropathy.

Predictive markers for patients with CVID who will respond to influenza vaccine were found to be enteropathy, Euroclass SmB⁻Tr^{norm}21^{norm} and post-germinal center B-cell pattern. Despite the fact that not all patients with CVID developed protective antibody levels after two doses of the vaccine, it is concluded that patients with CVID should be offered vaccination also against seasonal influenza^{9, 16, 17, 42, 46} due to the potential severity of the infection and risk for bacterial complications. Adverse events are not a major issue and inactivated influenza vaccine can safely be given to patients with CVID.

474	Acknowledgments
475	We would like to express our sincere gratitude to the participating patients and staff at the
476	Immunodeficiency Unit, Department of Infectious Diseases, Karolinska University Hospital,
477	Huddinge, Stockholm, Sweden.
478	The study was funded by the Jeffrey Modell Foundation, New York; the Swedish
479	Research Council, Stockholm, Sweden; and research funds from Karolinska Institutet,
480	Stockholm, Sweden.
481	
482	Author contributions
483	(1) The conception and design of the study
484	(2) Acquisition of data,
485	(3) Analysis and interpretation of data,
486	(4) Drafting the article
487	(5) Revising it critically for important intellectual content,
488	(6) Final approval of the version to be submitted
489	
490	AG(2,3,4,5,6), HA (3,4,5,6), RG(2,4,5,6), LE(3,5,6) and LH, (1,3,5,6).

491 **References**

- Jolles S. The variable in common variable immunodeficiency: a disease of complex
 phenotypes. The Journal of Allergy and Clinical Immunology: In Practice 2013;
 1:545-56.
- Yong PF, Thaventhiran JE, Grimbacher B. " A Rose is a Rose is a Rose," but CVID is
 Not CVID: Common Variable Immune Deficiency (CVID), What do we Know in
 2011? Advances in immunology 2011; 111:47.
- Abolhassani H, Parvaneh N, Rezaei N, Hammarstrom L, Aghamohammadi A. Genetic
 defects in B-cell development and their clinical consequences. J Investig Allergol Clin
 Immunol 2014; 24:6-22; quiz 2 p following
- Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la
 Morena MT, et al. International Consensus Document (ICON): Common Variable
 Immunodeficiency Disorders. J Allergy Clin Immunol Pract 2016; 4:38-59.
- 5. Fischer MB, Wolfram W, Binder CJ, Bohmig GA, Wahrmann M, Eibl MM, et al.
 Surface Plasmon Resonance Analysis Shows an IgG-Isotype-Specific Defect in ABO
 Blood Group Antibody Formation in Patients with Common Variable
 Immunodeficiency. Front Immunol 2015; 6:211.
- 508 6. Yarchoan R, Schneider HS, Wray BB, Nelson DL. Specific anti-influenza virus
 509 antibody production in vitro by lymphocytes from a subset of patients with
 510 hypogammaglobulinemia. J Clin Invest 1983; 71:1720-7.
- 511 7. Goldacker S, Draeger R, Warnatz K, Huzly D, Salzer U, Thiel J, et al. Active
 512 vaccination in patients with common variable immunodeficiency (CVID). Clin
 513 Immunol 2007; 124:294-303.
- Sanchez-Ramon S, de Gracia J, Garcia-Alonso A, Rodriguez Molina JJ, Melero J, de
 Andres A, et al. Multicenter study for the evaluation of the antibody response against
 salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-

- polysaccharide antibody production deficiency in patients with primary
 immunodeficiency. Clin Immunol 2016; 169:80-4.
- Hanitsch LG, Lobel M, Mieves JF, Bauer S, Babel N, Schweiger B, et al. Cellular and
 humoral influenza-specific immune response upon vaccination in patients with
 common variable immunodeficiency and unclassified antibody deficiency. Vaccine
 2016; 34:2417-23.
- Hong R, Agrawal S, Gollapudi S, Gupta S. Impaired pneumovax-23-induced
 monocyte-derived cytokine production in patients with common variable
 immunodeficiency. J Clin Immunol 2010; 30:435-41.
- 11. Rezaei N, Siadat SD, Aghamohammadi A, Moin M, Pourpak Z, Norouzian D, et al.
 Serum bactericidal antibody response 1 year after meningococcal polysaccharide
 vaccination of patients with common variable immunodeficiency. Clin Vaccine
 Immunol 2010; 17:524-8.
- Janssen WJ, Nierkens S, Sanders EA, Boes M, van Montfrans JM. Antigen-specific
 IgA titres after 23-valent pneumococcal vaccine indicate transient antibody deficiency
 disease in children. Vaccine 2015; 33:6320-6.
- 533 13. Chovancova Z, Vlkova M, Litzman J, Lokaj J, Thon V. Antibody forming cells and
 plasmablasts in peripheral blood in CVID patients after vaccination. Vaccine 2011;
 535 29:4142-50.
- 536 14. Carsetti R, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A, et al. The loss
 537 of IgM memory B cells correlates with clinical disease in common variable
 538 immunodeficiency. J Allergy Clin Immunol 2005; 115:412-7.
- Rezaei N, Aghamohammadi A, Read RC. Response to polysaccharide vaccination
 amongst pediatric patients with common variable immunodeficiency correlates with
 clinical disease. Iran J Allergy Asthma Immunol 2008; 7:231-4.

- 542 16. Eibl MM, Wolf HM. Vaccination in patients with primary immune deficiency,
 543 secondary immune deficiency and autoimmunity with immune regulatory
 544 abnormalities. Immunotherapy 2015; 7:1273-92.
- van Assen S, de Haan A, Holvast A, Horst G, Gorter L, Westra J, et al. Cell-mediated
 immune responses to inactivated trivalent influenza-vaccination are decreased in
 patients with common variable immunodeficiency. Clin Immunol 2011; 141:161-8.
- 548 18. Ballow M. Vaccines in the assessment of patients for immune deficiency. J Allergy
 549 Clin Immunol 2012; 130:283-4 e5.
- Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ. Pandemic
 influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in
 hypogammaglobulinaemic patients: four case reports. Scand J Immunol 2011; 74:2108.
- 554 20. Wolf HM, Thon V, Litzman J, Eibl MM. Detection of impaired IgG antibody 555 formation facilitates the decision on early immunoglobulin replacement in 556 hypogammaglobulinemic patients. Front Immunol 2015; 6:32.
- 557 21. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary
 558 immunodeficiencies. Clinical immunology 1999; 93:190-7.
- Bogaert DJ, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F.
 Genes associated with common variable immunodeficiency: one diagnosis to rule
 them all? J Med Genet 2016; 53:575-90.
- 562 23. Products, EAftEoM, Note for guidance on harmonization of requirements for
 563 influenza vaccines (CPMP/BWP/214/96), 1997. Available on January 11, 2018,
- at <u>http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/200</u>
 9/09/WC500003945.pdf.
- 566 24. Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E, et al.
 567 Confirmation and improvement of criteria for clinical phenotyping in common

- variable immunodeficiency disorders in replicate cohorts. J Allergy Clin Immunol
 2012; 130:1197-8 e9.
- Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial:
 defining subgroups in common variable immunodeficiency. Blood 2008; 111:77-85.
- Driessen GJ, van Zelm MC, van Hagen PM, Hartwig NG, Trip M, Warris A, et al. Bcell replication history and somatic hypermutation status identify distinct
 pathophysiologic backgrounds in common variable immunodeficiency. Blood 2011;
 118:6814-23.
- Peron S, Pan-Hammarstrom Q, Imai K, Du L, Taubenheim N, Sanal O, et al. A
 primary immunodeficiency characterized by defective immunoglobulin class switch
 recombination and impaired DNA repair. J Exp Med 2007; 204:1207-16.
- 579 28. Vorechovsky I, Scott D, Haeney MR, Webster DA. Chromosomal radiosensitivity in
 580 common variable immune deficiency. Mutat Res 1993; 290:255-64.
- Palanduz S, Palanduz A, Yalcin I, Somer A, Ones U, Ustek D, et al. In vitro
 chromosomal radiosensitivity in common variable immune deficiency. Clin Immunol
 Immunopathol 1998; 86:180-2.
- 30. Aghamohammadi A, Moin M, Kouhi A, Mohagheghi MA, Shirazi A, Rezaei N, et al.
 Chromosomal radiosensitivity in patients with common variable immunodeficiency.
 Immunobiology 2008; 213:447-54.
- 587 31. Offer SM, Pan-Hammarstrom Q, Hammarstrom L, Harris RS. Unique DNA repair
 588 gene variations and potential associations with the primary antibody deficiency
 589 syndromes IgAD and CVID. PLoS One 2010; 5:e12260.
- Agarwal S, Smereka P, Harpaz N, Cunningham-Rundles C, Mayer L. Characterization
 of immunologic defects in patients with common variable immunodeficiency (CVID)
 with intestinal disease. Inflamm Bowel Dis 2011; 17:251-9.

593	33.	International MHC, Autoimmunity Genetics N, Rioux JD, Goyette P, Vyse TJ,
594		Hammarstrom L, et al. Mapping of multiple susceptibility variants within the MHC
595		region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 2009; 106:18680-
596		5.
597	34.	Salzer U, Neumann C, Thiel J, Woellner C, Pan-Hammarstrom Q, Lougaris V, et al.
598		Screening of functional and positional candidate genes in families with common
599		variable immunodeficiency. BMC Immunol 2008; 9:3.
600	35.	Lag (2003:460) om etikprövning av forskning som avser människor. Svensk
601		författningssamling SFS 2003:460, Utbildningsdepartementet, Stockholm, Sverige. In
602		Swedish. (The Swedish Act (2003:460) on the Ethical Review of Research Involving
603		Humans. The Swedish Code of Statutes SFS 2003:460, The Ministry for Higher
604		Education and Research. Retrieved August 15, 2017, from
605		https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-
606		forfattningssamling/lag-2003460-om-etikprovning-av-forskning-som_sfs-2003-460.
607	36.	Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, et al. Humoral
608		response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in
609		immunocompromised patients. Clin Infect Dis 2011; 52:248-56.
610	37.	European Medicines Agency. Pandemrix. Annex I. Summary of product
611		characteristics. European Medicines Agency, London, United Kingdom. Available on
612		January 11, 2018,
613		at <u>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR</u>
614		Product_Information/human/000832/WC500038121.pdf.
615	38.	Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, Broman M, et al. High
616		frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1)

617 virus among the elderly in Finland. Euro Surveill 2010; 15.

- Hong DK, Tremoulet AH, Burns JC, Lewis DB. Cross-reactive neutralizing antibody
 against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin
 preparations. Pediatr Infect Dis J 2011; 30:67-9.
- 621 40. European Medicines Agency. Pandemrix. EMA/388182/2016. European Medicines
- Agency, London, United Kingdom, 2016. Available on January 11, 2018,
- at <u>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-</u>
 Summary_for_the_public/human/000832/WC500038122.pdf.
- 41. Zhan W, Yue F, Liu J, Lee J, Ho J, Moir S, et al. Response to influenza immunization
 in patients with common variable immunodeficiency. Allergy Asthma Clin Immunol
 2011; 7:A28.
- 42. van Assen S, Holvast A, Telgt DS, Benne CA, de Haan A, Westra J, et al. Patients
 with humoral primary immunodeficiency do not develop protective anti-influenza
 antibody titers after vaccination with trivalent subunit influenza vaccine. Clin
 Immunol 2010; 136:228-35.
- 43. Al-Herz W, McGeady SJ. Antibody response in common variable immunodeficiency.
 Ann Allergy Asthma Immunol 2003; 90:244-7.
- 634 44. Baldassin MPM, Grumach A, De Oliveira AKB, Kalil J. B cell subtypes' kinetics over
- a 6 monthxs period in CVID patients submitted to influenza and H1N1 immunization.

636 World Allergy Organization Journal 2015; 8:A226.

- Ko J, Radigan L, Cunningham-Rundles C. Immune competence and switched memory
 B cells in common variable immunodeficiency. Clin Immunol 2005; 116:37-41.
- 46. Mieves JF, Wittke K, Freitag H, Volk HD, Scheibenbogen C, Hanitsch LG. Influenza
 Vaccination in Patients with Common Variable Immunodeficiency (CVID). Curr
 Allergy Asthma Rep 2017; 17:78.

642	47.	Choi SW, Seo	KW, Oh	JS, Lee	JS, Cha I	HJ. Success	sful treatm	ent of	enterc	opathy
643		associated with	n common	variable	immunoo	deficiency.	Korean J	Intern	Med	2014;
644		29:256-8.								

- 48. Borte S, Pan-Hammarstrom Q, Liu C, Sack U, Borte M, Wagner U, et al. Interleukin21 restores immunoglobulin production ex vivo in patients with common variable
 immunodeficiency and selective IgA deficiency. Blood 2009; 114:4089-98.
- 49. Sanchez-Ramon S, Radigan L, Yu JE, Bard S, Cunningham-Rundles C. Memory B
 cells in common variable immunodeficiency: clinical associations and sex differences.
 Clin Immunol 2008; 128:314-21.
- 50. Cambronero R, Sewell WA, North ME, Webster AD, Farrant J. Up-regulation of IL12 in monocytes: a fundamental defect in common variable immunodeficiency. J
 Immunol 2000; 164:488-94.
- Martinez-Pomar N, Raga S, Ferrer J, Pons J, Munoz-Saa I, Julia MR, et al. Elevated
 serum interleukin (IL)-12p40 levels in common variable immunodeficiency disease
 and decreased peripheral blood dendritic cells: analysis of IL-12p40 and interferongamma gene. Clin Exp Immunol 2006; 144:233-8.
- McQuaid A, Tormey VJ, Trafford B, Webster AD, Bofill M. Evidence for increased
 expression of regulatory cytokine receptors interleukin-12R and interleukin-18R in
 common variable immunodeficiency. Clin Exp Immunol 2003; 134:321-7.
- 53. Ibanez C, Sune P, Fierro A, Rodriguez S, Lopez M, Alvarez A, et al. Modulating
 effects of intravenous immunoglobulins on serum cytokine levels in patients with
 primary hypogammaglobulinemia. BioDrugs 2005; 19:59-65.
- 664 54. Hirahara K, Nakayama T. CD4+ T-cell subsets in inflammatory diseases: beyond the
 665 Th1/Th2 paradigm. Int Immunol 2016; 28:163-71.
- 666 55. McCaw JM, McVernon J, McBryde ES, D. MJ. Influenza: accounting for prior
 667 immunity. Science; 325:1071.

- 56. Bodewes R, Fraaij P, Geelhoed-Mieras M, van Baalen C, Tiddens H, van Rossum A,
 et al. Annual Vaccination against Influenza Virus Hampers Development of VirusSpecific CD8+ T Cell Immunity in Children. Journal Virology 2011; 85:11995-2000.
- 57. Li J, Jorgensen SF, Maggadottir SM, Bakay M, Warnatz K, Glessner J, et al.
 Association of CLEC16A with human common variable immunodeficiency disorder
 and role in murine B cells. Nat Commun 2015; 6:6804.
- Aghamohammadi A, Mohammadi J, Parvaneh N, Rezaei N, Moin M, Espanol T, et al.
 Progression of selective IgA deficiency to common variable immunodeficiency. Int
 Arch Allergy Immunol 2008; 147:87-92.
- 677 59. Cheraghi T, Aghamohammadi A, Mirminachi B, Keihanian T, Hedayat E,
 678 Abolhassani H, et al. Prediction of the evolution of common variable
 679 immunodeficiency: HLA typing for patients with selective IgA deficiency. J Investig
 680 Allergol Clin Immunol 2014; 24:198-200.
- 681 60. Desombere I, Van der Wielen M, Van Damme P, Stoffel M, De Clercq N, Goilav C, et
 682 al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a
 683 hepatitis B vaccine with a novel adjuvant. Vaccine 2002; 20:2597-602.
- 684 61. Li ZK, Nie JJ, Li J, Zhuang H. The effect of HLA on immunological response to 685 hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 2013; 31:4355-61.
- 686 62. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral
 687 response by TACI. Immunity 2001; 14:573-82.
- 688 63. Martinez-Gallo M, Radigan L, Almejun MB, Martinez-Pomar N, Matamoros N,
 689 Cunningham-Rundles C. TACI mutations and impaired B-cell function in subjects
 690 with CVID and healthy heterozygotes. J Allergy Clin Immunol 2013; 131:468-76.
- 691 64. Romberg N, Chamberlain N, Saadoun D, Gentile M, Kinnunen T, Ng YS, et al.
- 692 CVID-associated TACI mutations affect autoreactive B cell selection and activation. J
- 693 Clin Invest 2013; 123:4283-93.

694	65.	Koopmans W, Woon ST, Brooks AE, Dunbar PR, Browett P, Ameratunga R. Clinical
695		variability of family members with the C104R mutation in transmembrane activator
696		and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol
697		2013; 33:68-73.

- 699 **Table 1-** Demographic data of 48 patients with CVID including eight responders (≥1:40 titer) and 40
- 700 non-responders to the A(H1N1) pandemic influenza vaccine.

Parameters	Total group	Responders	Non-responders	<i>p</i> -value*
Number	48	8	40	-
Gender (F/M)	29/19	5/3	24/16	0.62
Mean age at diagnosis of CVID (years)	44.2 ± 18.0	40.5±15.4	44.9 ± 18.5	0.26
Mean age at study start (years)	57.7±14.9	54.3±16.2	58.3±17.4	0.60
Mean years from onset of infections to	12.9±10.6	9.4±8.2	13.6±9.7	0.44
diagnosis (years)				
Mean follow-up after diagnosis (years)	13.4±8.8	13.8±8.0	13.4±9.1	0.72
Familial cases (%)	9(18.7)	0	9(22.5)	0.16
Progressive primary antibody ^a	14(29.1)	0	14(35)	0.048
deficiency (%)				

701

^a Progression of other types of primary antibody deficiency including IgA deficiency and IgG subclass 702 703 deficiency to CVID.

* p values <0.05 were regarded significant and are **bolded** 704

705 Table 2- Immunologic data of 48 patients with CVID at diagnosis including 8 responders and 40 non-

responders to A(H1N1) pandemic vaccine.

Parameters	Normal range	Total CVID	Responders	Non-	<i>p</i> -value*
				responders	
IgM (mg/dl)	50-370	31.7±9.7	17.0±16.0	34.8±29.6	0.03
IgA (mg/dl)	80-380	9.2±8.4	9.5±8.4	9.2 ± 7.0	0.76
IgG (mg/dl)	600-1500	209.2±173.4	243.7±206.1	201.7±167.8	0.20
IgG1 (mg/dl)	280-800	141.3±125.7	219.2±198.3	122.4±96.3	0.007
IgG2 (mg/dl)	115-570	49.3±37.0	48.0±36.1	49.7±37.0	0.74
IgG3 (mg/dl)	24-125	19.9±18.1	19.3±16.5	22.3±21.4	0.30
White Blood cells (cell/ul)	3500-8800	5828.5±2395.2	5971.4±1729.8	5791.4±2565.9	0.49
Lymphocyte (cell/ul)	1130-2720	1364.4±607.2	1237.3±318.0	1397.4±662.6	0.10
T cells (cell/ul)	780-2070	1126.6±489.8	1032.8±264.8	1150.9±534.1	0.056
CD4 ⁺ T cells (cell/ul)	490-1340	516.4±244.3	504.2±187.6	519.6±260.0	0.46
Naive CD4 (% of CD4 ⁺ T cells)	11-35	13.0±8.0	16.1±9.5	12.1±7.4	0.24
Memory CD4 (% of CD4 ⁺ T cells)	31-74	$70.4{\pm}14.8$	70.5±14.5	70.4±15.2	0.8
CD8 ⁺ T cells (cell/ul)	190-800	625.4±342.3	530.5±230.4	650.0±365.2	0.033
Naive CD8 (% of CD8 ⁺ T cells)	27-69	35.4±12.1	32.8±14.0	36.1±11.7	0.42
Memory CD8 (% of CD8 ⁺ T cells)	12-50	35.5±2.0	33.2±9.7	43.1±16.4	0.044
CD4:CD8	1-4	1.1±0.9	1.0 ± 0.4	$1.1{\pm}1.0$	0.28
NK cells (cell/ul)	70-420	94.1±61.6	78.5±23.4	98.1±67.9	0.06
B cell (cell/ul)	90-400	123.7±94.9	114.2±91.2	126.2±94.5	0.56
Naïve B (% of CD19 ⁺ T cells)	47-84	70.2±21.4	71.6±17.6	69.7±22.8	0.72
Transitional B (% of $CD19^+$ T	0-1	4.3±3.6	4.2±4.0	4.4±3.9	0.48
cells)					
Natural memory B (% of CD19 ⁺	6-29	21.12±17.4	18.9±11.7	22.0±19.0	0.28
T cells)					
Switched memory B (% of CD19 ⁺	9-29	$6.4{\pm}6.0$	$8.0{\pm}7.8$	5.9 ± 5.0	0.41
T cells)					
Plasmablast (% of CD19 ⁺ T cells)	0-3.2	0.06 ± 0.01	0.1 ± 0.02	0.04 ± 0.03	0.007
CD21 ^{low} B (% of CD19 ⁺ T cells)	0.7-10	$15.0{\pm}10.9$	8.5±4.6	17.2±11.6	0.041

707 * p values < 0.05 were regarded significant and are **bolded**

1 Figure legends

Figure 1- Specific antibody response against A(H1N1) pandemic influenza vaccination after 1 and 3
months in 48 patients with CVID.


Figure 2- Clinical phenotyping of 48 patients with CVID including 8 responders and 40 nonresponders to A(H1N1) pandemic influenza vaccine. During the course of the disease, all patients presented with the phenotype infections. Thus, the patients had at least the phenotype infections (here presented as "No disease-related complications") or the phenotype infections together with one or more of the phenotypes in the figure (for detail of clinical phenotyping see **Table S2**). PLI: polyclonal lymphocytic infiltration.

Figure 3- Immunological phenotyping in percentage of 48 patients with CVID including 8 responders 10 11 and 40 non-responders to A(H1N1) influenza pandemic vaccine and classification according to the A. Paris classification (0: low switch memory[SM] and low total memory [M], 1: low SM and normal M, 12 2: normal SM and normal M), **B.** Freiburg classification (1a: low SM and increased CD21^{low}, 1b: low 13 SM and normal CD21^{low}, 2: normal SM and normal M), C. Euroclass classification (according to SM, 14 CD21^{low} and Transitional [Tr] B cells) and **D.** B cell pattern classification (P1:low Tr and low M, P2: 15 low naive and low M, P3: low marginal zone and low M, P4: low M and P5: normal). 16 17 Figure 4- Cytokine production of interferon gamma (IFN-y), interleukin 2 (IL-2), IL-12, IL-5 and IL-

18 10 in 48 patients with CVID, including 8 responders (R) and 40 non-responders (NR) to A(H1N1)

19 pandemic influenza vaccine after phytohemagglutinin stimulation.

Fig 1.








Fig. 2





1	Supplementary Material
2	
3	Predictive markers for humoral vaccine response in patients with
4	common variable immunodeficiency (CVID)
5	
6	Gardulf et al.

Parameters	Total CVID	Responders to	Non-responders	<i>p</i> -value
		Pandemrix [®]	to Pandemrix [®]	
	Numbers (%)	Numbers (%)	Numbers (%)	
Diphtheria Ab (normal/total tested)	11/27(40.7)	2/5(40)	9/22(40.9)	1.0
Tetanus Ab (normal/total tested)	13/34(38.2)	3/5(60)	10/29(34.4)	0.34
CMV Ab (normal/total tested)	6/17(35.2)	1/4(25)	5/13(38.4)	1.0
MCV Ab (normal/total tested)	2/10(20)	0/1(0)	2/9(22.2)	1.0
Teichoic acid Ab (normal/total tested)	9/16(56.2)	1/3(33.3)	8/13(61.5)	0.55
Hib Ab (normal/total tested)	6/11(54.5)	1/1(100)	5/10(50)	1.0
Pneumococcus Ab (normal/total tested)	1/9(11.1)	1/1(100)	0/8(0)	0.11
PPS6 Ab (normal/total tested)	7/16(43.7)	1/3(33.3)	6/13(23)	1.0
PPSV23 Ab (normal/total tested)	4 ^b /9(44.4)	1/3(33.3)	3/6(50)	1.0

7 **Table S1-** Specific antibody response to protein and polysaccharides antigens ^a

8 ^a CMV: Cytomegalovirus, Hib: Haemophilus influenzae type b, MCV: Meningococcal conjugate

9 vaccine, PPS6: Phospho-p70 S6 Kinase, PPSV23: nonconjugated polysaccharide, Pneumovax 23-

10 *valent vaccines.*

^b These four patients had defective isohemagglutinins tests and therefore, according to the criteria of

12 the European Society for Immunodeficiencies (ESID), they have a diagnosis of CVID.

- 13 Table S2- Medical manifestations and clinical phenotypes of 48 patients with CVID at diagnosis
- 14 including 8 responders and 40 non-responders to A(H1N1) pandemic vaccine.

Parameters	Total CVID Numbers (%)	Responders to Pandemrix [®] Numbers (%)	Non-responders to Pandemrix [®] Numbers (%)	<i>p</i> -value*					
					Medical manifestations				
					Recurrent upper respiratory tract infections	48(100)	8(100)	40(100)	1
Lower respiratory tract infections	44	5(62.5)	33(82.5)	0.20					
Bronchiectasis	7(14.5)	0	7(17.5)	0.10					
Autoimmune cytopenia	5(10.4)	0	5(12.5)	0.29					
Inflammatory bowel diseases	6(12.5)	1(12.5)	5(12.5)	1					
Celiac disease	4(8.3)	1(12.5)	3(7.5)	0.64					
Psoriasis	3(6.2)	0	3(7.5)	0.42					
Vitiligo	2(4.1)	0	2(5)	0.51					
Diabetes mellitus type 1	2(4.1)	0	2(5)	0.51					
Systemic lupus erythematosus	1(2.1)	1(12.5)	1(2.5)	0.19					
Waldeyer's lymphadenopathy	5(10.4)	1(12.5)	4(10)	0.83					
Generalized lymphadenopathy	4(8.3)	0	4(10)	0.35					
Splenomegaly	2(4.1)	0	2(5)	0.51					
Granulomatous disease	1(2.1)	0	1(2.5)	0.65					
Malignancies	14(29.1)	2(25)	12(30)	0.38					
Breast cancer	2(4.1)	1(12.5)	1(2.5)	0.19					
Colon cancer	2(4.1)	1(12.5)	1(2.5)	0.19					
Thymoma/lymphoma	9(12.5)	0	9(22.5)	0.13					
Prostate cancer	1(2.1)	0	1(2.5)	0.65					
IgE mediated atopic disorders	13(27.1)	4(50)	9(22.5)	0.12					
Asthma	4(8.3)	0	4(10)	0.35					
Clinical phenotypes									
Infections without any other disease-related	14(29.1)	1(12.5)	13(32.5)	0.12					
complications									
Autoimmunity phenotype	14(29.1)	2(25)	12(30)	0.38					
Enteropathy phenotype	4(8.3)	4(50)	0	<0.001					
Polyclonal lymphocytic infiltration	3(6.2)	0	3(7.5)	0.42					
phenotype									
Overlapping phenotypes	13(27.0)	1(12.5)	12(30)	0.30					

^{15 *} p values < 0.05 were regarded significant and are **bolded**